Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:DiVA.org:uu-156596" > Chromogenic laborat...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Becker, Richard C. (author)

Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor

Article/chapterEnglish2011

Publisher, publication year, extent ...

2011-04-23
Springer Science and Business Media LLC,2011
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:uu-156596
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-156596URI
https://doi.org/10.1007/s11239-011-0591-8DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

An ability to readily determine an anticoagulant effect with an emerging class of direct, active site, oral factor Xa inhibitors is viewed by the medical community as attractive and by some as an absolute requirement for their use in clinical practice. We performed a pharmacokinetic and pharmacodynamic substudy in APPRAISE-1-a study of apixaban in patients with acute coronary syndrome(ACS). A total of 1691 patients had blood sampled for apixaban plasma concentrations using mass spectrometry/high performance liquid chromatography and anti-Xa activity using a chromogenic assay employing either low molecular weight heparin or apixaban as reference standards. Anti-Xa activity, determined by either anti-Xa-LMWH (r = 0.9671; P < 0.0001) or anti-Xa-apixaban (r = 0.9669; P < 0.0001) correlated strongly and in a linear fashion with apixaban plasma concentrations. The correlations for each method were equally strong at low (< 100 ng/ml) (r = 0.86, P < 0.0001; r = 0.85, P < 0.0001), intermediate(100-200 ng/ml) (r = 0.73, P < 0.0001; r = 0.69, P < 0.0001) and high (> 200 ng/ml) (r = 0.91, P < 0.0001; r = 0.91, P < 0.0001) plasma concentrations of apixaban, respectively. Our pharmacokinetic and pharmacodynamic substudy suggests that an apixaban-mediated anticoagulant effect can be detected even at very low plasma concentrations using a standard laboratory chromogenic anti-Xa assay with either LMWH or apixaban calibrators. While establishing parameters for safety and efficacy will require further investigation, an ability to discern the presence of a drug effect may provide clinically useful information.

Subject headings and genre

Apixaban
Acute coronary syndrome
Ant-Xa activity
MEDICINE
MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

Yang, Hongqiu (author)
Barrett, Yuchen (author)
Mohan, Puneet (author)
Wang, Jessie (author)
Wallentin, LarsUppsala universitet,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)larswall (author)
Alexander, John H. (author)
Uppsala universitetUppsala kliniska forskningscentrum (UCR) (creator_code:org_t)

Related titles

In:Journal of Thrombosis and Thrombolysis: Springer Science and Business Media LLC32:2, s. 183-1870929-53051573-742X

Internet link

Find in a library

Journal of Thrombosis and Thrombolysis (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Becker, Richard ...; Yang, Hongqiu; Barrett, Yuchen; Mohan, Puneet; Wang, Jessie; Wallentin, Lars; show more...; Alexander, John ...; show less...

Articles in the publication: Journal of Throm ...

By the university: Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se